Insider Selling: AxoGen (NASDAQ:AXGN) Director Sells 11,431 Shares of Stock

AxoGen, Inc. (NASDAQ:AXGN) Director William Mr. Burke sold 11,431 shares of AxoGen stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $24.05, for a total transaction of $274,915.55. Following the transaction, the director owned 100 shares in the company, valued at approximately $2,405. This trade represents a 99.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

AxoGen Trading Down 1.8%

NASDAQ AXGN traded down $0.42 on Friday, reaching $23.57. The company had a trading volume of 989,751 shares, compared to its average volume of 846,646. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -471.40 and a beta of 1.09. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.14 and a quick ratio of 2.67. AxoGen, Inc. has a fifty-two week low of $9.22 and a fifty-two week high of $24.25. The business has a 50 day moving average of $17.74 and a two-hundred day moving average of $14.44.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. The firm had revenue of $60.08 million for the quarter, compared to analyst estimates of $56.90 million. AxoGen had a negative return on equity of 1.96% and a negative net margin of 0.98%. AxoGen has set its FY 2025 guidance at EPS. Analysts forecast that AxoGen, Inc. will post -0.29 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on AXGN. Jefferies Financial Group reiterated a “buy” rating on shares of AxoGen in a research report on Wednesday, October 29th. Wall Street Zen raised shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Canaccord Genuity Group lifted their price objective on AxoGen from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Raymond James Financial boosted their price objective on AxoGen from $20.00 to $27.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Finally, Citizens Jmp raised their target price on AxoGen from $26.00 to $34.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $28.86.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Arizona State Retirement System bought a new stake in shares of AxoGen during the first quarter worth about $222,000. New York State Common Retirement Fund boosted its stake in AxoGen by 15.2% during the 1st quarter. New York State Common Retirement Fund now owns 80,202 shares of the medical equipment provider’s stock valued at $1,484,000 after purchasing an additional 10,573 shares during the last quarter. Hussman Strategic Advisors Inc. increased its holdings in AxoGen by 100.0% during the 1st quarter. Hussman Strategic Advisors Inc. now owns 63,000 shares of the medical equipment provider’s stock worth $1,166,000 after purchasing an additional 31,500 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of AxoGen in the first quarter worth approximately $150,000. Finally, Legato Capital Management LLC lifted its holdings in shares of AxoGen by 47.7% in the first quarter. Legato Capital Management LLC now owns 50,986 shares of the medical equipment provider’s stock valued at $943,000 after purchasing an additional 16,462 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.